{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:07:56Z","timestamp":1791616076400,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium fur Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund","doi-asserted-by":"publisher","award":["01KG1817"],"award-info":[{"award-number":["01KG1817"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T12:01:49Z","timestamp":1780228909000},"page":"1120-1132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)\u2014an AIO\/ABCSG trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9321-9911","authenticated-orcid":false,"given":"G.","family":"Folprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-6877","authenticated-orcid":false,"given":"A.","family":"Reinacher-Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5613","authenticated-orcid":false,"given":"L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Goekkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8830","authenticated-orcid":false,"given":"L.","family":"Jacobasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Conradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kr\u00f6cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-8504","authenticated-orcid":false,"given":"R.-D.","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0610-345X","authenticated-orcid":false,"given":"R.","family":"Liersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-4359","authenticated-orcid":false,"given":"U.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.U.","family":"Riera Knorrenschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Klimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-5132","authenticated-orcid":false,"given":"L.","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-2401","authenticated-orcid":false,"given":"C.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Aust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tannapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-2991","authenticated-orcid":false,"given":"J.","family":"Christmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.annonc.2026.05.001_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N Engl J Med"},{"issue":"8955","key":"10.1016\/j.annonc.2026.05.001_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)90696-7","article-title":"Efficacy of adjuvant fluorouracil and folinic acid in colon cancer","volume":"345","year":"1995","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.annonc.2026.05.001_bib3","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.001_bib4","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.001_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO-25-00621","article-title":"Three versus 6 months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy for colorectal cancer: final results of SCOT-an international, randomized, phase III, noninferiority trial","volume":"44","author":"Iveson","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.05.001_bib31","series-title":"TNM Classification of Malignant Tumours","first-page":"74","article-title":"Colon and rectum","author":"Brierley","year":"2025"},{"issue":"9604","key":"10.1016\/j.annonc.2026.05.001_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","author":"Quasar Collaborative Group","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.001_bib7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.05.001_bib8","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","article-title":"Adjuvant chemotherapy for stage II colon cancer with poor prognostic features","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.05.001_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","article-title":"Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer","volume":"29","author":"Hutchins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"346","key":"10.1016\/j.annonc.2026.05.001_bib10","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.annonc.2026.05.001_bib11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1200\/JCO-25-02086","article-title":"Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)","volume":"44","author":"Sinicrope","year":"2026","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2026.05.001_bib12","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-21-0271","article-title":"Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial","volume":"27","author":"Ta\u00efeb","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.annonc.2026.05.001_bib13","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.05.001_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006887","article-title":"Real-world monitoring of ctDNA reliably predicts cancer recurrence and treatment efficacy in patients with resected stages I-III colon cancer","author":"Cohen","year":"2025","journal-title":"Ann Surg"},{"issue":"24","key":"10.1016\/j.annonc.2026.05.001_bib15","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.05.001_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.05.001_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.811291","article-title":"Sensitive quantification of cell-free tumor DNA for early detection of recurrence in colorectal cancer","volume":"12","author":"Stasik","year":"2022","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.001_bib18","first-page":"170","article-title":"The CIRCULATE trial: circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation (AIO-KRK-0217)","volume":"21","author":"Folprecht","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2026.05.001_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41416-023-02300-3","article-title":"Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer","volume":"129","author":"Ryoo","year":"2023","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.annonc.2026.05.001_bib27","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2026.05.001_bib20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.05.001_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","article-title":"Whole genome sequencing-powered ctDNA sequencing for breast cancer detection","volume":"36","author":"Garcia-Murillas","year":"2025","journal-title":"Ann Oncol"},{"issue":"548","key":"10.1016\/j.annonc.2026.05.001_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8084","article-title":"ctDNA monitoring using patient-specific sequencing and integration of variant reads","volume":"12","author":"Wan","year":"2020","journal-title":"Sci Transl Med"},{"issue":"7779","key":"10.1016\/j.annonc.2026.05.001_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1672-7","article-title":"The landscape of somatic mutation in normal colorectal epithelial cells","volume":"574","author":"Lee-Six","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.001_bib23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1080\/0284186X.2023.2259083","article-title":"ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study","volume":"62","author":"Callesen","year":"2023","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.05.001_bib24","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.annonc.2026.05.001_bib25","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2026.05.001_bib26","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.05.001_bib29","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2026.05.001_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.dld.2020.04.010","article-title":"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: the CIRCULATE-PRODIGE 70 trial","volume":"52","author":"Ta\u00efeb","year":"2020","journal-title":"Dig Liver Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:42Z","timestamp":1785283182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0923753426001808"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)\u2014an AIO\/ABCSG trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}